Green Alpha Advisors’s Recursion Pharmaceuticals RXRX Stock Holding History

Green Alpha Advisors’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$541K	Sell	147,544 -4,554	-3%	-$15.2K	0.36%	66
2026 Q1	$467K	Buy	152,098 +1,020	+0.7%	+$3.94K	0.46%	61
2025 Q4	$618K	Sell	151,078 -61,124	-29%	-$303K	0.57%	56
2025 Q3	$1.04M	Buy	212,202 +37,109	+21%	+$195K	1%	33
2025 Q2	$886K	Sell	175,093 -3,780	-2%	-$18.6K	0.85%	38
2025 Q1	$946K	Buy	178,873 +111,728	+166%	+$815K	1.01%	28
2024 Q4	$454K	Buy	67,145 +2,346	+4%	+$15.8K	0.36%	95
2024 Q3	$427K	Buy	64,799 +1,800	+3%	+$12.9K	0.34%	96
2024 Q2	$472K	Sell	62,999 -9,435	-13%	-$82.3K	0.38%	93
2024 Q1	$722K	Buy	72,434 +4,563	+7%	+$50.8K	0.52%	75
2023 Q4	$669K	Buy	67,871 +33,329	+96%	+$238K	0.48%	85
2023 Q3	$264K	Buy	+34,542	New	+$345K	0.2%	131

Other funds holding RXRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Green Alpha Advisors's RXRX Position: Q2 2026 in Review

Green Alpha Advisors reduced its Recursion Pharmaceuticals (RXRX) stake by 3% in Q2 2026, selling an estimated $15.2K and leaving 147,544 shares worth $541K. The position accounts for 0.36% of the portfolio, ranked #66.

Green Alpha Advisors first reported a position in RXRX in Q3 2023 and has held it in 12 quarters since. The position peaked at $1.04M in Q3 2025. 342 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

Green Alpha Advisors held 147,544 shares of Recursion Pharmaceuticals worth $541K as of Q2 2026.
Green Alpha Advisors sold 4,554 Recursion Pharmaceuticals shares in Q2 2026, an estimated $15.2K.
Recursion Pharmaceuticals made up 0.36% of Green Alpha Advisors's portfolio in Q2 2026, its #66 holding.
Green Alpha Advisors first reported a position in Recursion Pharmaceuticals in Q3 2023 and has held it in 12 quarters since.
Green Alpha Advisors's Recursion Pharmaceuticals position peaked at $1.04M in Q3 2025.
342 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Green Alpha Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.